News of Note - February 21, 2023
BULL BEAR BRES|NAHAN
Tuesday, February 21, 2023
15:03:20
Perhaps this isn't 'deglobalization' so much as re(shuffling)globalization.. The global economy is being rebalanced - is that so bad? The Economist article [HERE] gets the gears whirring for sure..
😊
Br. -john
*PRESS RELEASES*
ALNY
Alnylam
PDUFA Date Set for October 8, 2023
Planning to hold an advisory committee meeting
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference.
BHVN
Biohaven
Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
Taldefgrobep alfa, a myostatin-targeting biologic investigational agent, in Phase 3 development to increase muscle mass for Spinal Muscular Atrophy patients now granted Fast Track in addition to previously receiving Orphan Drug Designation in the US
Biohaven Ltd., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with debilitating neurological and neuropsychiatric diseases in the United States.
PEG
PSE&G
Release
Webcast
https://events.q4inc.com/attendee/467181831
Public Service Enterprise Group Incorporated, through its subsidiaries, operates as an energy company primarily in the Northeastern and Mid-Atlantic United States.
TAP
Molson Coors
Release
Webcast
https://events.q4inc.com/attendee/920196620
Hub
https://ir.molsoncoors.com/financials/quarterly-results/default.aspx
Molson Coors Beverage Company manufactures, markets, and sells beer and other malt beverage products under various brands in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.
QURE & CSL AU
uniQure & CSL
Announces the European Commission approval of the first gene therapy for adults with hemophilia B
Historic approval represents the first gene therapy in Europe to treat hemophilia B and provides a new treatment option for patients that reduces the rate of annual bleeds, reduces or eliminates the need for prophylactic therapy, and generates elevated and sustained factor IX levels
Approval marks uniQure’s second internally-developed and manufactured gene therapy to achieve licensure in the European Union
uniQure N.V., a gene therapy company, engages in the development of treatments for patients suffering from genetic and other devastating diseases. -CapIQ
CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and allied products in Australia, the United States, Germany, the United Kingdom, Switzerland, China, and internationally. -CapIQ
PFE
Pfizer
U.S. FDA has set an action date for August 2023. If approved, RSVpreF would be the first vaccine for administration to pregnant individuals to help protect against the complications of RSV disease in infants from birth through six months
This action follows the recent acceptance of the Marketing Authorization Application (MAA) for Pfizer’s RSV vaccine candidate by the European Medicines Agency (EMA) under accelerated assessment for both older adults and maternal immunization
The maternal immunization regulatory filings are supported by results of the pivotal Phase 3 trial MATISSE, which will be presented to the CDC’s Advisory Committee on Immunization Practices (ACIP), as well as during the ReSViNET Foundation’s 2023 Global Conference, on February 23
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. - CapIQ
MRK
Merck
Did not demonstrate a statistically significant reduction in the risk of COVID-19 following household exposure to another individual with COVID-19
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. -CapIQ
AZN LN | AZN SS | AZN & SAN FP | SNY
AstraZeneca & Sanofi
Beyfortus continues to demonstrate consistent protection against RSV disease through the RSV season
New Canadian analysis demonstrates Synagis to be highly cost-effective in 29-35 weeks gestational age infants
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. -CapIQ
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. -CapIQ
SCANFL FH
Scanfil Oyj
Release
https://www.sttinfo.fi/ir-files/69819303/4180/4729/Download%20announcement%20as%20PDF.pdf
Report
https://www.sttinfo.fi/ir-files/69819303/4180/4727/Scanfil%20financal%20statement_2022.pdf
Webcast
https://scanfil.videosync.fi/full-year-2022/register
Scanfil Oyj operates as a contract manufacturer and system supplier for the electronics industry worldwide. -CapIQ
4568 JT
Daiichi Sankyo
Announces Global Management Structure and Corporate Officers
Hiroyuki Okuzawa -> COO
Koji Ogawa -> CFO
Daiichi Sankyo Company, Limited, a pharmaceutical company, manufactures and sells pharmaceutical products worldwide. -CapIQ
PSPN SW
PSP Swiss Property
Release
Report
Presentation
Webcast
PSP Swiss Property AG, together with its subsidiaries, owns and operates real estate properties in Switzerland. -CapIQ
LSG NO
Lerøy Seafood Group
Release/ Report
https://ml-eu.globenewswire.com/Resource/Download/f28217be-dce3-4e58-a920-3e4cf3e02be7
Presentation
https://ml-eu.globenewswire.com/Resource/Download/ebc4d182-ab7c-4cc9-b672-89ab0e69cae6
Webcast
https://www.leroyseafood.com/en/investor/reports-and-webcast/webcast/
Lerøy Seafood Group ASA produces, processes, markets, sells, and distributes seafood products worldwide. -CapIQ
BAKKA NO
Bakkafrost
Release/ Report
https://mb.cision.com/Public/12459/3719642/ba835f2bb96becaa.pdf
Presentation
https://mb.cision.com/Public/12459/3719642/9be898508cd3accf.pdf
Webcast
https://www.bakkafrost.com/en/investor-relations/webcast/
P/F Bakkafrost, together with its subsidiaries, produces and sells salmon products under the Bakkafrost and Havsbrún brands in North America, Western Europe, Eastern Europe, Asia, and internationally. -CapIQ
*ARTICLES, ETC.*
Bloomberg
BofA and JPMorgan Say the European Rally Will Fizzle Out Soon
Stoxx 600’s downside risks are mounting after surge: survey
Strategists see monetary tightening hitting stocks with a lag
‘Ant-Man’ Is First Big Film of 2023 With $120 Million Debut
Paramount+ Price Will Increase $2 a Month and Include Showtime
Paramount Global’s sales disappoint on TV ad weakness
Showtime Channel to become part of Paramount+ package
The Economist
Global firms are eyeing Asian alternatives to Chinese manufacturing
Can “Altasia” steal China’s thunder?
Evaluate
Immuno-oncology combinations and beyond
The latest edition of the PD(L)anner focuses on combinations, and analyses the difficulties China developers are having with US approvals.
Science
Does Earth hold vast stores of a renewable, carbon-free fuel?
There Are Vaccines and There Are Vaccines
NEJM
Shortening Tuberculosis Treatment — A Strategic Retreat
Treatment Strategy for Rifampin-Susceptible Tuberculosis
HBR
How Microsoft Became Innovative Again
How did Microsoft revive its culture of innovation? For years, the company has been written off for playing defense on its position in the tech world. But, as signaled by its partnership with OpenAI and its challenge to Google’s search supremacy, it has gone back on the offense. The about face was, at its core, a cultural shift, driven by CEO Satya Nadella. He drove this by inviting an existential moment when he stepped into the job, reconsidering the company’s purpose. Then, he laid out strategic changes that would enable the company to think more like a startup, and made business decisions that committed the company to this new direction.